Extended Follow-Up of the Standard Hancock Porcine Bioprosthesis
- 1 December 1991
- journal article
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 6 (4S) , 544-549
- https://doi.org/10.1111/jocs.1991.6.4s.544
Abstract
We have reviewed 665 patients in whom the standard Hancock porcine bioprosthesis (HPB) was used for aortic (AVR = 173), mitral (MVR = 437), and mitral and aortic (MAVR = 55) valve replacement in the time interval from 1970 to 1983. After AVR, HPB-related deaths occurred in 24 patients (1.7% ± 0.4% per patient-year); 11 had thromboembolic episodes (0.8% ± 0.2% per patient-year), 6 hemorrhages related to anticoagulants (0.4% ± 0.2% per patient-year), 9 endocarditis (0.7% ± 0.2% per patient-year), 7 prosthetic leak (0.5% ± 0.1 % per patient-year), and 59 structural deterioration (4.3% ± 0.6% per patient-year). At 16 years, actuarial survival is 40% ± 6%, freedom from thromboembolic episodes 89% ± 4%, from hemorrhages 90% ± 5%, from endocarditis 94% ± 2%, from prosthetic leak 95% ± 2%, and from structural deterioration 36% ± 6%. After MVR, HPB-related deaths occurred in 64 patients (1.6% ± 0.2% per patient-year); 68 had thromboembolic episodes (1.7% ± 0.2% per patient-year), 28 hemorrhages (0.7% ± 0.1% per patient-year), 12 endocarditis (0.3% ± 0.1% per patient-year), 9 prosthetic leak (0.2% ± 0.1% per patient-year), and 158 structural deterioration (4.0% ± 0.3% per patient-year). At 18 years, actuarial survival is 33% ± 4%, freedom from thromboembolic episodes 57% ± 13%, from hemorrhages 81% ± 6%, from endocarditis 91% ± 4%, from prosthetic leak 98% ± 1%, and from structural deterioration 18% ± 5%. After MAVR there were 18 HPB-related deaths (5.0% ± 1.3% per patient-year); 6 patients had thromboembolic episodes (1.7% ± 0.2% per patient-year), 6 hemorrhages (1.7% ± 0.2% per patient-year), 11 endocarditis (3.1% ± 1.1% per patient-year), 6 prosthetic leak (1.7% ± 0.7% per patient-year), and 17 structural deterioration (4.8% ± 1.2% per patient-year). At 14 years, actuarial survival is 26% ± 7%, freedom from thromboembolic episodes 85% ± 7%, from hemorrhages 80% ± 11%, from endocarditis 74% ± 7%, from prosthetic leak 93% ± 4%, and from structural deterioration 16% ± 10%. The HPB has shown excellent performance in the first decade that, however, becomes unacceptable thereafter due to the progressively increasing incidence of structural valve deterioration.Keywords
This publication has 12 references indexed in Scilit:
- The Standard Hancock Porcine Bioprosthesis: Overall Experience at the University of PadovaJournal of Cardiac Surgery, 1988
- Carpentier-Edwards Standard Porcine Bioprosthesis: Primary Tissue Failure (Structural Valve Deterioration) by Age GroupsThe Annals of Thoracic Surgery, 1988
- Performance of the Hancock Porcine Bioprosthesis Following Aortic Valve Replacement: Considerations Based on a 15-Year ExperienceThe Annals of Thoracic Surgery, 1988
- Emergency reoperation for primary tissue failure of porcine bioprosthesesThe American Journal of Cardiology, 1987
- Long-term Durability of the Hancock Porcine Bioprosthesis Following Combined Mitral and Aortic Valve Replacement: An 11-Year ExperienceThe Annals of Thoracic Surgery, 1987
- Isolated Mitral Valve Replacement with the Hancock Bioprosthesis: A 13-Year AppraisalThe Annals of Thoracic Surgery, 1984
- Calcific degeneration as the main cause of porcine bioprosthetic valve failureThe American Journal of Cardiology, 1984
- Isolated mitral valve replacement with the hancock porcine bioprosthesis in rheumatic heart disease: Analysis of 213 operative survivors followed up 4.5 to 8.5 yearsThe American Journal of Cardiology, 1984
- Long-term failure rate and morphologic correlations in porcine bioprosthetic heart valvesThe American Journal of Cardiology, 1983
- Five to Eight-Year Follow-up of Patients Undergoing Porcine Heart-Valve ReplacementNew England Journal of Medicine, 1981